Immuneering (IMRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.59, -1.37% vs the prior close of $3.64.
- Volume 747.79K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IMRX dips 1.4% to $3.59. Closed at $3.59, -1.37% vs the prior close of $3.64. Day range $3.58–$3.68, opened at $3.65.
IMRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — IMRX dips 1.4% to $3.59
- Closed at $3.59, -1.37% vs the prior close of $3.64. Day range $3.58–$3.68, opened at $3.65.
- Volume was 747.79K shares, 1.1x its 50-day average of 709.22K.
- Price is -20.6% vs its 50-day average ($4.52) and -26.8% vs its 200-day average ($4.90).
- 52-week range $3.38–$8.48; today's close sits at 4% of that range, 57.7% below the 52-week high.
Oct 15, 2026 — IMRX jumps 6.4% to $3.64
- Closed at $3.64, +6.43% vs the prior close of $3.42. Day range $3.38–$3.71, opened at $3.42.
- Volume was 934.30K shares, 1.3x its 50-day average of 700.70K.
- Price is -19.8% vs its 50-day average ($4.54) and -26.0% vs its 200-day average ($4.92).
- 52-week range $3.38–$8.48; today's close sits at 5% of that range, 57.1% below the 52-week high.
Oct 14, 2026 — IMRX slides 3.9% to $3.42, a 52-week low, 3 down days in a row
- Closed at $3.42, -3.93% vs the prior close of $3.56. Day range $3.41–$3.60, opened at $3.51.
- Volume was 803.70K shares, 1.1x its 50-day average of 699.93K.
- Price is -24.9% vs its 50-day average ($4.56) and -30.7% vs its 200-day average ($4.94).
- 52-week range $3.41–$8.48; today's close sits at 0% of that range, 59.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IMRX slides 7.8% to $3.56, a 52-week low
- Closed at $3.56, -7.77% vs the prior close of $3.86. Day range $3.55–$3.86, opened at $3.86.
- Volume was 734.40K shares, 1.1x its 50-day average of 695.19K.
- Price is -22.2% vs its 50-day average ($4.58) and -28.1% vs its 200-day average ($4.95).
- 52-week range $3.55–$8.48; today's close sits at 0% of that range, 58.0% below the 52-week high.
Oct 12, 2026 — IMRX dips 2.0% to $3.86
- Closed at $3.86, -2.03% vs the prior close of $3.94. Day range $3.81–$3.94, opened at $3.94.
- Volume was 529.70K shares, 0.8x its 50-day average of 692.78K.
- Price is -15.9% vs its 50-day average ($4.59) and -22.3% vs its 200-day average ($4.97).
- 52-week range $3.60–$8.48; today's close sits at 5% of that range, 54.5% below the 52-week high.
Oct 9, 2026 — IMRX jumps 5.3% to $3.94
- Closed at $3.94, +5.35% vs the prior close of $3.74. Day range $3.68–$3.95, opened at $3.75.
- Volume was 709.70K shares, 1.0x its 50-day average of 688.78K.
- Price is -14.2% vs its 50-day average ($4.59) and -20.9% vs its 200-day average ($4.98).
- 52-week range $3.60–$8.48; today's close sits at 7% of that range, 53.5% below the 52-week high.
Oct 8, 2026 — IMRX slides 3.1% to $3.74, a 52-week low on 2.9x normal volume
- Closed at $3.74, -3.11% vs the prior close of $3.86. Day range $3.60–$3.83, opened at $3.83.
- Volume was 1.92M shares, 2.9x its 50-day average of 666.36K — unusually heavy trading.
- Price is -18.7% vs its 50-day average ($4.60) and -25.1% vs its 200-day average ($4.99).
- 52-week range $3.60–$8.48; today's close sits at 3% of that range, 55.9% below the 52-week high.
Oct 7, 2026 — IMRX rises 0.8% to $3.86
- Closed at $3.86, +0.78% vs the prior close of $3.83. Day range $3.74–$3.91, opened at $3.78.
- Volume was 747.70K shares, 1.1x its 50-day average of 665.66K.
- Price is -16.2% vs its 50-day average ($4.61) and -22.8% vs its 200-day average ($5.00).
- 52-week range $3.74–$8.48; today's close sits at 3% of that range, 54.5% below the 52-week high.
Oct 6, 2026 — IMRX slides 5.2% to $3.83, a 52-week low
- Closed at $3.83, -5.20% vs the prior close of $4.04. Day range $3.81–$4.09, opened at $4.06.
- Volume was 898.40K shares, 1.4x its 50-day average of 656.88K.
- Price is -17.0% vs its 50-day average ($4.61) and -23.5% vs its 200-day average ($5.01).
- 52-week range $3.81–$8.48; today's close sits at 0% of that range, 54.8% below the 52-week high.
Oct 5, 2026 — IMRX dips 0.7% to $4.04
- Closed at $4.04, -0.74% vs the prior close of $4.07. Day range $4.02–$4.12, opened at $4.07.
- Volume was 479.70K shares, 0.7x its 50-day average of 656.59K.
- Price is -12.6% vs its 50-day average ($4.62) and -19.5% vs its 200-day average ($5.02).
- 52-week range $3.86–$8.48; today's close sits at 4% of that range, 52.4% below the 52-week high.
Oct 2, 2026 — IMRX rises 1.0% to $4.07
- Closed at $4.07, +0.99% vs the prior close of $4.03. Day range $4.02–$4.14, opened at $4.10.
- Volume was 588.80K shares, 0.9x its 50-day average of 655.11K.
- Price is -12.1% vs its 50-day average ($4.63) and -19.0% vs its 200-day average ($5.03).
- 52-week range $3.86–$8.48; today's close sits at 5% of that range, 52.0% below the 52-week high.
IMRX latest news & SEC filings
Every SEC filing by or about IMRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$17.27M (prior year -$14.43M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.27 (prior year -$0.40) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 16, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jun 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zeskind Benjamin J. bought 2,400 shares at $4.56 (≈$10.94K) on Jun 23, 2026
- Zeskind Benjamin J. bought 2,400 shares at $4.56 (≈$10.94K) on Jun 23, 2026
- Zeskind Benjamin J. bought 2,400 shares at $4.56 (≈$10.94K) on Jun 23, 2026
- Zeskind Benjamin J. bought 2,400 shares at $4.56 (≈$10.94K) on Jun 23, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade IMRX
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 6, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.78% (largest 7.8%).
- Liquidity: about 709.43K shares (≈$2.55M) trade per day on average.
- 52-week position: $3.59 vs a range of $3.38–$8.48 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Benjamin J. Zeskind bought 2,400 shares on Jun 23, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 15, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
IMRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.65 | 3.68 | 3.58 | 3.59 | 747.79K |
| Oct 15, 2026 | 3.42 | 3.71 | 3.38 | 3.64 | 934.30K |
| Oct 14, 2026 | 3.51 | 3.60 | 3.41 | 3.42 | 803.70K |
| Oct 13, 2026 | 3.86 | 3.86 | 3.55 | 3.56 | 734.40K |
| Oct 12, 2026 | 3.94 | 3.94 | 3.81 | 3.86 | 529.70K |
| Oct 9, 2026 | 3.75 | 3.95 | 3.68 | 3.94 | 709.70K |
| Oct 8, 2026 | 3.83 | 3.83 | 3.60 | 3.74 | 1.92M |
| Oct 7, 2026 | 3.78 | 3.91 | 3.74 | 3.86 | 747.70K |
| Oct 6, 2026 | 4.06 | 4.09 | 3.81 | 3.83 | 898.40K |
| Oct 5, 2026 | 4.07 | 4.12 | 4.02 | 4.04 | 479.70K |
| Oct 2, 2026 | 4.10 | 4.14 | 4.02 | 4.07 | 588.80K |
| Oct 1, 2026 | 4.10 | 4.17 | 4.01 | 4.03 | 538.20K |
| Sep 30, 2026 | 4.16 | 4.23 | 4.09 | 4.09 | 596.80K |
| Sep 29, 2026 | 4.16 | 4.16 | 4.07 | 4.13 | 574.40K |
| Sep 28, 2026 | 4.25 | 4.25 | 4.12 | 4.16 | 597.90K |
| Sep 25, 2026 | 4.36 | 4.40 | 4.26 | 4.27 | 513.40K |
| Sep 24, 2026 | 4.36 | 4.38 | 4.20 | 4.34 | 589.60K |
| Sep 23, 2026 | 4.62 | 4.65 | 4.36 | 4.38 | 551.50K |
| Sep 22, 2026 | 4.50 | 4.66 | 4.45 | 4.61 | 590.40K |
| Sep 21, 2026 | 4.55 | 4.57 | 4.38 | 4.44 | 540.30K |
About Immuneering
Immuneering (IMRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1790340.
IMRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert J Carpenter | Director | Jun 11, 2026 |
| Peter Feinberg | Director | Jun 11, 2026 |
| Diana Hausman | Director | Jun 11, 2026 |
| Laurie Keating | Director | Jun 11, 2026 |
| Thomas J. Schall | Director | Jun 11, 2026 |
| Benjamin J. Zeskind | PRESIDENT AND CEO | Jun 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | Feb 5, 2026 |
| Harold Eugene Brakewood | Chief Business Officer | Feb 5, 2026 |
| Andrew Gengos | Chief Financial Officer | Jul 17, 2026 |
| Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Jun 16, 2026 |
| Igor Matushansky | Chief Medical Officer | Feb 5, 2026 |
| Mallory Morales | SVP Finance, CAO | Feb 5, 2026 |
| Leah R Neufeld | CHIEF PEOPLE OFFICER | Mar 17, 2026 |
| Benjamin J. Zeskind | PRESIDENT AND CEO | Jun 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | Benjamin J. Zeskind | Buy | 2,400 | $4.56 |
| Jun 23, 2026 | Benjamin J. Zeskind | Buy | 2,400 | $4.56 |
| Jun 23, 2026 | Benjamin J. Zeskind | Buy | 2,400 | $4.56 |
| Jun 23, 2026 | Benjamin J. Zeskind | Buy | 2,400 | $4.56 |
| Jun 15, 2026 | Brett Matthew Hall | Buy | 6,035 | $4.15 |
| Jun 15, 2026 | Brett Matthew Hall | Buy | 6,035 | $4.15 |
| Jun 15, 2026 | Brett Matthew Hall | Buy | 6,035 | $4.15 |
| Jun 15, 2026 | Brett Matthew Hall | Buy | 6,035 | $4.15 |
| Jan 16, 2026 | Harold Eugene Brakewood | Buy | 5,250 | $4.76 |
| Jan 16, 2026 | Harold Eugene Brakewood | Buy | 5,250 | $4.76 |
| Jan 16, 2026 | Harold Eugene Brakewood | Buy | 5,250 | $4.76 |
| Jan 16, 2026 | Harold Eugene Brakewood | Buy | 5,250 | $4.76 |
| Jan 15, 2026 | Thomas J. Schall | Buy | 21,645 | $4.67 |
| Jan 15, 2026 | Thomas J. Schall | Buy | 21,645 | $4.67 |
| Jan 15, 2026 | Thomas J. Schall | Buy | 21,645 | $4.67 |
IMRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-56.02M | -1.27 | $-45.34M |
| Dec 31, 2024 | — | $-61.04M | -2.04 | $-55.00M |
| Dec 31, 2023 | $0 | $-53.47M | -1.88 | $-48.97M |
| Dec 31, 2022 | $316.95K | $-50.51M | -1.91 | $-44.10M |
| Dec 31, 2021 | $2.08M | $-33.54M | -2.46 | $-30.85M |
Latest balance sheet: total assets $202.06M, total liabilities $11.32M, cash $41.32M (as of Jun 30, 2026).
IMRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $4.39 |
| May 15, 2026 | 8-K Item 2.02 (results) | $5.16 |
| Mar 6, 2026 | 8-K Item 2.02 (results) | $5.33 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $6.62 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $3.22 |
| May 5, 2025 | 8-K Item 2.02 (results) | $1.25 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $1.65 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $1.71 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 1, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IMRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.